The First Digital International Panda Festival Opens on November 3, 2020 in Meishan, China
3.11.2020 20:00:00 EET | Business Wire | Press release
With the theme of "Panda World, World Panda--For Nature As It Is", the first digital International Panda Festival is hosted by Sichuan Forestry and Grassland Administration (Giant Panda National Park Sichuan Administration), Information Office of Sichuan Provincial People's Government, Sichuan Foreign Affairs Office, Sichuan Internet Information Office, International Union for Conservation of Nature (IUCN) China Representative Office, organized by Sichuan Digital Panda Technology Development Co., Ltd., co-organized by Sichuan Provincial People's Association for Friendship with Foreign Countries, Chengdu Research Base of Giant Panda Breeding and Sichuan Giant Panda Protection Foundation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201103005025/en/
The First Digital International Panda Festival (Photo: Business Wire)
Giant pandas are the "messenger of peace" in China's opening to the outside world. Sichuan ranks first in the area of giant panda habitat, the number of wild giant panda population and captive giant pandas in China.
Sichuan, as one of the pilot areas of the Giant Panda National Park, covers an area of 20,177 square kilometers, accounting for 74.36%. There are 1,227 giant pandas in the wild, accounting for 75.23%.
The opening ceremony launches a “space-air-ground-man” integrated digital platform. Locals will be able to learn about the life of Sichuan-based giant pandas living in foreign countries. Meanwhile, it releases books such as the Gift of Nature - Discovering Sichuan as It Is, Landscape of Bamboo forests in Sichuan, Secret Sichuan - the 88 Most Beautiful Forest and Grass Landscapes to Go. It also releases the top six lists of “the Most Beautiful Bamboo Landscape” in Chengdu-Chongqing Economic Circle, as well as the Guidelines on Promoting the Development of Natural Education by eight departments including Sichuan Provincial Forestry and Grassland Administration, Sichuan Provincial Development and Reform Commission, Education Department of Sichuan Province, etc. Besides, Forest and Grassland Fire Research Institute, Sichuan Academy of Forestry Sciences are inaugurated.
Six forums and three conferences systematically present successful experiences in building high-quality forest and grassland fire barriers. Exhibitions such as the Nature Reserve Photo Exhibition, the Giant Panda Cultural and Creative Exhibition, and the Giant Panda International Art Exhibition make you appreciate the unique charm.
The digital International Panda Festival will strive to develop into a branded network exchange platform with distinctive themes at both national and international levels, making itself the only global flagship platform with western characteristics in China.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005025/en/
Contact information
Media Contact
Sichuan Digital Panda Technology Development Co., Ltd.
Name: Tina Tian
Email: digitalpanda@digitalgiantpanda.com
Websites: http://www.digitalgiantpanda.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom